Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)

加州理工学院/加州大学洛杉矶分校个性化治疗诊断工程促进代谢系统 (iTEAM)

• 批准号: 10213026
• 负责人: Dino Di Carlo
• 金额: $ 29.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-08 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10213026
• 关键词: Engineering; Metabolic; System; theranostics

ABSTRACT The California Institute of Technology (Caltech) and the University of California at Los Angeles (UCLA) have partnered to integrate advanced imaging and sensing coupled with computing needed to translate technological innovation to address the global cardiometabolic disease. The UCLA/Caltech integrated Theranostic Engineering to Advance Metabolic Medicine (iTEAM) Program represents a new paradigm that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post-doctoral engineers or physical scientists into leadership roles in academia and industry. The convergence of the fundamental strengths of Caltech and clinical strengths of UCLA is conducive to individualize training in 1) advanced sensing or 2) imaging coupled with computing to address 3) cardiometabolic disease. The iTEAM program is partnering with industry leaders (Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences) for internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and underrepresented minorities. To implement this UCLA/Caltech iTEAM program, we have developed a mentoring and self-evaluating structure in the inclusion of 21 primary and co-mentors, 13 consulting mentors, and 10 industry leaders (42% female). Each iTEAM scholar will have co-mentorships: a primary mentor from enabling technologies and a secondary from cardiometabolic medicine and/or industry. In Year 1, iTEAM scholars will: 1) Participate in an initial two- day workshop including mentors, program leaders, clinicians, physician-scientists, and industry leaders to explore projects, expectations, mentorship, and goals; 2) Meet one-to-one with the Program Director(s) to finalize a primary (imaging or sensing) and a co-mentor (cardiometabolic disease or industry); 3) Develop an Individualized Development Plans (IDP) with the Advising & Training Committee to finalize the project; and 4) Strengthen fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iTEAM scholars will be afforded 1) the opportunity to present work-in-progress and provide feedback in quarterly meetings with a primary mentor and with a co- mentor, 2) an option to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 3) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iTEAM scholar. UCLA Vice Provost for Graduate Education and has also committed supplemental trainee support to enhance the diversity of trainees. Overall, this program infuses the scientific workforce with the next generation of theranostic bioengineers prepared to solve the worldwide threat of cardiometabolic disease.

抽象的 加州理工学院 (Caltech) 和加州大学洛杉矶分校 (UCLA) 合作将先进的成像和传感与翻译所需的计算相结合 解决全球心脏代谢疾病的技术创新。加州大学洛杉矶分校/加州理工学院综合 促进代谢医学的治疗诊断工程 (iTEAM) 计划代表了一种新范式 将正式形成为期两年的结构化课程，重点是招募代表性不足的人 博士后工程师或物理科学家在学术界和工业界担任领导角色。这 加州理工学院的基础优势和加州大学洛杉矶分校的临床优势的融合有利于 在 1) 先进传感或 2) 成像与计算相结合的个性化培训中解决 3) 心脏代谢疾病。 iTEAM 计划正在与行业领导者（Amgen、Johnson & Johnson、Medtronic 和 Edwards Lifesciences）用于实习、指导和领导力项目。两者都 加州理工学院多样性中心和加州大学洛杉矶分校教师多样性与发展办公室支持了以下研讨会： 面向女性和代表性不足的少数群体的科学技术工程与数学 (STEM)。到 实施这个 UCLA/Caltech iTEAM 计划，我们开发了一个指导和自我评估结构 包括 21 名主要导师和共同导师、13 名咨询导师和 10 名行业领袖（42% 为女性）。 每位 iTEAM 学者都将有共同导师：来自支持技术的主要导师和来自支持技术的辅助导师 来自心脏代谢医学和/或工业。在第一年，iTEAM 学者将： 1) 参加最初的两个项目： 日间研讨会包括导师、项目负责人、临床医生、医师科学家和行业领袖 探索项目、期望、指导和目标； 2) 与项目总监一对一会面 最终确定主要指导者（成像或传感）和辅助指导者（心脏代谢疾病或行业）； 3) 开发一个 与咨询和培训委员会一起制定个性化发展计划（IDP）以完成项目；和 4) 加强高级成像、传感器或计算方面的基础知识以及教学培训 生物医学研究和出版物的道德规范。在第二年，iTEAM 学者将获得 1) 的机会 在与主要导师和共同导师的季度会议上展示正在进行的工作并提供反馈 导师，2) 可以选择参加临床和转化研究途径证书 加州大学洛杉矶分校临床转化科学研究所 (CTSI) 或 FDA 监管科学法律与技术 (BE188/299)；和/或 3) 参加 UCLA CTSI 赞助的专业发展，为未来的职业发展做准备 学术或行业职业。加州理工学院和加州大学洛杉矶分校的院长都承诺为每个 iTEAM 提供配套资金 学者。加州大学洛杉矶分校负责研究生教育的副教务长，还承诺为学生提供补充实习生支持 增强学员的多样性。总体而言，该计划为下一代科学工作者注入了活力 治疗诊断生物工程师准备解决全球范围内心脏代谢疾病的威胁。